NFE2L2 and B-cell chronic lymphocytic leukemia: Additionally, inhibiting antioxidant defenses by targeting pathways such as Nrf2 or STAT3 could reduce the antioxidant capacity of CLL cells, rendering them more susceptible to oxidative damage.